Analysis of factors associated with clinical response in glofitamab's treatment of relapsed or refractory (R/R) large B-cell lymphoma

Abstract Abstract Diffuse large B-cell lymphoma (DLBCL) has achieved good treatment outcomes with anti-CD20 based chemoimmunotherapy in the majority of cases, while relapsed/refractory disease occurs in 30-40% patients, The CD3/CD20 bi-specific antibody glofitamab is being increasingly utilized for treatment of relapsed or refractory (R/R) large B-cell lymphoma. In this study, we retrospectively evaluated 15 patients who had received at least two lines of therapy previously. Baseline characteristics, BsAb treatment details, baseline levels of peripheral blood immune subsets, gene expression and mutational profile, peripheral blood immunophenotyping, plasma cytokine measurement and and treatment response were analyzed. Until July 1, 2025, the median follow-up time was 6 months (range:5-12 months). 7 (46%) patients achieved complete response (CR) by using glofitamab. Baseline levels of peripheral blood immune subsets including CD3, CD4, CD8 T cell, and NK cells did not show a significant association with CR. Our study revealed a trend toward a higher CD4/CD8 memory T cells in peripheral blood of CR patients, while there was no significant difference in cytokine expression level, including IL6, IL8, TNFα between CR population and other response groups. Multivariate analysis showed patients with bulky disease were independently associated with inferior outcomes. This conclusion requires confirmation through studies with larger sample sizes.